Jiangsu Hengrui Pharmaceuticals (600276.SH) has obtained a drug registration certificate.

20/01/2025

GMT Eight

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced recently that its subsidiary Fujian Shengdi Pharmaceuticals Co., Ltd. has received the "Drug Registration Certificate" for complex amino acids (16AA)/glucose (12.6%) electrolyte injection issued by the National Medical Products Administration (NMPA). This product is the first generic in China to be approved through the evaluation of generic drug quality and efficacy consistency.

HK Stock Market Move | VOBILE GROUP (03738) rises over 4% again, with strengthening industry awareness on content copyright protection. The company recently showcased new AI copyright technology.

Biotechnology company Sionna Therapeutics (SION.US) has filed for an IPO on the US stock market to raise a planned $100 million.

Contact: contact@gmteight.com

Jiangsu Hengrui Pharmaceuticals (600276.SH) has obtained a drug registration certificate.

RECOMMEND

Beijing Dabeinong Technology Group (002385.SZ) forecasts a net profit of 300 million to 400 million yuan for the year 2024, turning losses into profits compared to the previous year.

Ningbo Zhoushan Port (601018.SH) net profit in 2024 was 4.881 billion yuan, an increase of 4.55% year-on-year.

Yangling Metron New Material (300861.SZ) issued a profit warning, with an estimated annual net profit of 143 million to 168 million yuan, a year-on-year decrease of 89.42% to 91%.